



Media Release

Planegg/Munich, Germany, November 2, 2017

MorphoSys Announces Presentation of Clinical Data on Proprietary Blood Cancer Compound MOR208 at Upcoming American Society of Hematology Annual Meeting 2017

- Abstract on preliminary data from ongoing phase 2 trial with antibody MOR208 in combination with lenalidomide in relapsed/refractory DLBCL accepted for poster presentation at ASH 2017
- Poster presentation will take place on December 11, 2017, 6:00-8:00pm EST (December 12, 0:00-2:00am CET)
- Conference call by MorphoSys scheduled for December 12, 2017, 11:00am EST (5:00pm CET)

MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today announced the upcoming presentation of data on the Company's proprietary investigational hemato-oncological program MOR208 at the 59th American Society of Hematology (ASH) Annual Meeting, being held December 9-12, 2017 in Atlanta, Georgia/USA.

"We are pleased that updated clinical trial results of the phase 2 L-MIND study with our antibody MOR208 in combination with lenalidomide in patients with relapsed or refractory diffuse large B cell lymphoma (R/R DLBCL) who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation will be shown at the upcoming ASH conference in a poster presentation," commented Dr. Malte Peters, Chief Development Officer of MorphoSys AG. "We see a particularly high unmet medical need for these blood cancer patients and look forward to presenting an update from our ongoing study in this patient group."

Based on preliminary data from the L-MIND study presented in June 2017, the FDA had recently granted Breakthrough Therapy designation for MOR208, in combination with lenalidomide, for the treatment of patients with R/R DLBCL who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation.

Details about the abstract from MorphoSys's proprietary program MOR208 accepted for presentation at ASH 2017:

[Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind](#)

The poster presentation will include updated clinical results, in particular with respect to safety and efficacy, from our phase 2 study L-MIND with MOR208 in combination with lenalidomide in adult patients with relapsed/refractory DLBCL who are not eligible for high-dose chemotherapy and autologous stem-cell transplantation.

Abstract #4123; Poster III

The poster will be presented during the Session #626 "Aggressive Lymphoma (Diffuse Large B-Cell and Other Aggressive B-Cell Non-Hodgkin Lymphomas)—Results from Prospective Clinical

Trials” on Monday, December 11, 2017, 6:00pm-8:00pm EST (Dec. 12, 2017, 0:00am-2:00am CET), in the Georgia World Congress Center, Bldg A, Lvl 1, Hall A2.

In addition to the presentation, the abstract will be published online in the December 8, 2017 supplemental volume of Blood. Additional information can be found at www.hematology.org, including the abstract.

MorphoSys will hold an investor & analyst conference call after the 59th American Society of Hematology (ASH) Annual Meeting 2017 on December 12, 2017, 11:00am EST(5:00pm CET).

Dial-in details will be made available in time.

The presentation, a live webcast and a replay of the webcast will be made available at <http://www.morphosys.com>.

About MorphoSys:

MorphoSys’s mission is to make exceptional, innovative biopharmaceuticals to improve the lives of patients suffering from serious diseases. Innovative technologies and smart development strategies are central to our approach. Success is created by our people, who focus on excellence in all they do, collaborate closely across disciplines and are driven by a desire to make the medicines of tomorrow a reality. Success benefits all of our stakeholders.

Based on its proprietary technology platforms, particularly in the field of fully human therapeutic antibodies, MorphoSys, together with its partners, has built a therapeutic pipeline of more than 110 programs in R&D, around a quarter of which is currently in clinical development.

In its proprietary development segment, MorphoSys, alone or with partners, is developing new therapeutic candidates, mainly focusing on cancer and inflammation. In its partnered discovery segment, MorphoSys uses its technologies to discover new drug candidates for pharmaceutical partners and participates from the programs’ further development success, through success-based payments and royalties. MorphoSys is listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates about MorphoSys, visit <http://www.morphosys.com>.

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

For more information, please contact:

MorphoSys AG

Anke Linnartz

Head of Corporate Communications & IR

Jochen Orłowski

Associate Director Corporate Communications & IR

Alexandra Goller

Senior Manager Corporate Communications & IR

Tel: +49 (0) 89 / 899 27-404

investors@morphosys.com